UNLABELLED: Interleukin-12 is a heterodimeric cytokine produced by activated blood monocytes, macrophages and glial cells. It enhances differentiation and proliferation of T cells and increases production of proinflammatory cytokines, such as Interferon-gamma and Tumor Necrosis Factor-alpha. There is little information about the involvement of IL-12 in the pathophysiology of Alzheimer's disease (AD) and other tauopathies. OBJECTIVES: The objective of our study was to assess the role of IL-12 as a potential marker of immune reactions in patients with AD and frontotemporal dementia (FTD). PATIENTS AND METHODS: We measured by immunoassay cerebrospinal fluid (CSF) IL-12 levels in 19 patients with AD and 7 patients with FTD in comparison with CSF IL-12 levels in 30 patients with non-inflammatory neurological diseases served as neurological control patients (NCTRL). IL-12 levels were correlated with age, age of disease onset, disease duration, MMSE score, and rate of dementia progression. Abeta42 and Total tau (tau(T)) levels in CSF were also measured. RESULTS: Patients with AD had significantly lower CSF IL-12 levels compared with NCTRL patients (p<0.001). Patients with FTD had also lower CSF IL-12 levels compared with NCTRL patients (p<0.05). Age, sex, disease duration and MMSE score did not affect IL-12 levels in any of the groups. In AD a significant positive correlation was noted between IL-12 levels and tau(T) levels (Rs=0.46, p=0.048). CONCLUSIONS: Our findings may suggest a reduced inflammatory reaction during the course of AD and FTD. A neurotrophic role of IL-12 and other proinflammatory cytokines cannot be excluded.
UNLABELLED: Interleukin-12 is a heterodimeric cytokine produced by activated blood monocytes, macrophages and glial cells. It enhances differentiation and proliferation of T cells and increases production of proinflammatory cytokines, such as Interferon-gamma and Tumor Necrosis Factor-alpha. There is little information about the involvement of IL-12 in the pathophysiology of Alzheimer's disease (AD) and other tauopathies. OBJECTIVES: The objective of our study was to assess the role of IL-12 as a potential marker of immune reactions in patients with AD and frontotemporal dementia (FTD). PATIENTS AND METHODS: We measured by immunoassay cerebrospinal fluid (CSF) IL-12 levels in 19 patients with AD and 7 patients with FTD in comparison with CSF IL-12 levels in 30 patients with non-inflammatory neurological diseases served as neurological control patients (NCTRL). IL-12 levels were correlated with age, age of disease onset, disease duration, MMSE score, and rate of dementia progression. Abeta42 and Total tau (tau(T)) levels in CSF were also measured. RESULTS:Patients with AD had significantly lower CSF IL-12 levels compared with NCTRL patients (p<0.001). Patients with FTD had also lower CSF IL-12 levels compared with NCTRL patients (p<0.05). Age, sex, disease duration and MMSE score did not affect IL-12 levels in any of the groups. In AD a significant positive correlation was noted between IL-12 levels and tau(T) levels (Rs=0.46, p=0.048). CONCLUSIONS: Our findings may suggest a reduced inflammatory reaction during the course of AD and FTD. A neurotrophic role of IL-12 and other proinflammatory cytokines cannot be excluded.
Authors: T N C Magalhães; M Weiler; C V L Teixeira; T Hayata; A S Moraes; V O Boldrini; L M Dos Santos; B M de Campos; T J R de Rezende; H P G Joaquim; L L Talib; O V Forlenza; F Cendes; Marcio L F Balthazar Journal: Mol Neurobiol Date: 2017-10-16 Impact factor: 5.590
Authors: Johannes Vom Berg; Stefan Prokop; Kelly R Miller; Juliane Obst; Roland E Kälin; Ileana Lopategui-Cabezas; Anja Wegner; Florian Mair; Carola G Schipke; Oliver Peters; York Winter; Burkhard Becher; Frank L Heppner Journal: Nat Med Date: 2012-11-25 Impact factor: 53.440
Authors: Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer Journal: Lancet Neurol Date: 2015-04 Impact factor: 44.182
Authors: Joanna L Richens; Kelly-Ann Vere; Roger A Light; Daniele Soria; Jonathan Garibaldi; A David Smith; Donald Warden; Gordon Wilcock; Nin Bajaj; Kevin Morgan; Paul O'Shea Journal: Int J Mol Epidemiol Genet Date: 2014-05-29
Authors: Gustaf Boström; Eva Freyhult; Johan Virhammar; Daniel Alcolea; Hayrettin Tumani; Markus Otto; Rose-Marie Brundin; Lena Kilander; Malin Löwenmark; Vilmantas Giedraitis; Alberto Lleó; Christine A F von Arnim; Kim Kultima; Martin Ingelsson Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: Claudia Duran-Aniotz; Paulina Orellana; Tomas Leon Rodriguez; Fernando Henriquez; Victoria Cabello; María F Aguirre-Pinto; Tamara Escobedo; Leonel T Takada; Stefanie D Pina-Escudero; Oscar Lopez; Jennifer S Yokoyama; Agustin Ibanez; Mario A Parra; Andrea Slachevsky Journal: Front Neurol Date: 2021-06-24 Impact factor: 4.003